Capital City Trust Co. FL Sells 2,000 Shares of Cencora, Inc. (NYSE:COR)

Key Points

• Capital City Trust Co. FL decreased its stake in Cencora, Inc. by 44.8% during the first quarter, now holding 2,465 shares valued at $685,000.
• CEO Robert P. Mauch and Chairman Steven H. Collis sold a combined total of 19,547 shares of Cencora stock recently, reducing their positions by 10.50% and 4.47% respectively.
• Equities analysts have a consensus rating of "Moderate Buy" for Cencora, with a price target of approximately $309.83, reflecting positive sentiment among investors.

Capital City Trust Co. FL cut its stake in Cencora, Inc. (NYSE:COR - Free Report) by 44.8% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 2,465 shares of the company's stock after selling 2,000 shares during the period. Capital City Trust Co. FL's holdings in Cencora were worth $685,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in COR. Price T Rowe Associates Inc. MD lifted its position in Cencora by 0.9% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 8,859,452 shares of the company's stock valued at $1,990,542,000 after purchasing an additional 78,066 shares during the period. Bank of America Corp DE grew its stake in Cencora by 62.3% during the fourth quarter. Bank of America Corp DE now owns 5,193,807 shares of the company's stock valued at $1,166,944,000 after acquiring an additional 1,994,256 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Cencora by 3.1% in the 4th quarter. Geode Capital Management LLC now owns 4,326,064 shares of the company's stock worth $969,471,000 after buying an additional 130,213 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of Cencora by 20.4% in the 4th quarter. Invesco Ltd. now owns 3,243,531 shares of the company's stock worth $728,757,000 after acquiring an additional 550,246 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Cencora by 11.6% in the 4th quarter. Northern Trust Corp now owns 2,421,237 shares of the company's stock worth $544,004,000 after acquiring an additional 252,028 shares during the last quarter. 97.52% of the stock is currently owned by hedge funds and other institutional investors.

Cencora Stock Performance

Shares of COR traded down $3.85 during trading hours on Thursday, reaching $287.95. 674,762 shares of the company's stock traded hands, compared to its average volume of 1,570,989. The firm has a market capitalization of $55.81 billion, a price-to-earnings ratio of 33.39, a P/E/G ratio of 1.44 and a beta of 0.57. The company has a debt-to-equity ratio of 6.01, a current ratio of 0.87 and a quick ratio of 0.52. Cencora, Inc. has a twelve month low of $218.65 and a twelve month high of $309.35. The business's fifty day simple moving average is $293.13 and its two-hundred day simple moving average is $275.35.

Cencora (NYSE:COR - Get Free Report) last issued its quarterly earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share for the quarter, topping analysts' consensus estimates of $4.07 by $0.35. Cencora had a return on equity of 344.71% and a net margin of 0.55%. The firm had revenue of $75.50 billion for the quarter, compared to analysts' expectations of $75.41 billion. During the same quarter last year, the business posted $3.80 EPS. Cencora's revenue was up 10.3% on a year-over-year basis. Analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Monday, June 2nd. Stockholders of record on Friday, May 16th were given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.76%. The ex-dividend date of this dividend was Friday, May 16th. Cencora's dividend payout ratio is presently 25.52%.

Analysts Set New Price Targets

COR has been the subject of several recent research reports. Citigroup boosted their price target on shares of Cencora from $330.00 to $355.00 and gave the company a "buy" rating in a report on Thursday, May 8th. UBS Group boosted their target price on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a research report on Tuesday, April 29th. Morgan Stanley set a $330.00 price objective on shares of Cencora and gave the company an "equal weight" rating in a research note on Wednesday, July 16th. Robert W. Baird boosted their target price on shares of Cencora from $314.00 to $350.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Finally, Bank of America upped their price objective on shares of Cencora from $270.00 to $285.00 and gave the stock a "neutral" rating in a research report on Friday, April 11th. Three equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, Cencora presently has a consensus rating of "Moderate Buy" and a consensus target price of $309.83.

Insider Buying and Selling at Cencora

In other Cencora news, CEO Robert P. Mauch sold 4,968 shares of the business's stock in a transaction on Friday, July 18th. The stock was sold at an average price of $294.11, for a total value of $1,461,138.48. Following the transaction, the chief executive officer owned 42,351 shares of the company's stock, valued at approximately $12,455,852.61. The trade was a 10.50% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Chairman Steven H. Collis sold 14,578 shares of the business's stock in a transaction on Tuesday, July 22nd. The stock was sold at an average price of $292.67, for a total value of $4,266,543.26. Following the sale, the chairman owned 309,913 shares of the company's stock, valued at approximately $90,702,237.71. The trade was a 4.49% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 34,125 shares of company stock worth $9,993,789. 10.80% of the stock is owned by insiders.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.